Key facts
- This page summarizes Bryan Ball's Form 4 filing for Whitehawk Therapeutics, Inc. (WHWK).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 03 Apr 2025, 19:24.
Bryan Ball - 01 Apr 2025 Form 4 Insider Report for Whitehawk Therapeutics, Inc. (WHWK)
- Reporting relationship
- Chief Technical Operations Officer and SVP, Manufacturing Operations
- Issuer ticker
- WHWK
- Reported as of
- 01 Apr 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 03 Apr 2025, 19:24:36 UTC
- Prior SEC filing
- 04 Mar 2025
- Next SEC filing
- 10 Mar 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Stephen Rodin, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Bryan Ball filed Form 4 for Whitehawk Therapeutics, Inc. (WHWK) on 03 Apr 2025.
Change
- Previous filing in this sequence was filed on 04 Mar 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
WHWK
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +366,532
- Change %
- Price
- $0.000000
- Shares after
- 366,532
- Date
- 01 Apr 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 366,532
- Exercise price
- $1.70
- Footnotes
- F1
WHWK
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +366,532
- Change %
- Price
- $0.000000
- Shares after
- 366,532
- Date
- 01 Apr 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 366,532
- Exercise price
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one-year anniversary of the Vesting Commencement Date and 1/48th of the total shares subject to the Option shall vest every month thereafter such that all shares subject to the option shall be fully vested on the four-year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean April 1, 2025.
Footnote F2
Each restricted stock unit ("RSU") represents a contingent right to receive one share of Whitehawk Therapeutics, Inc. Common Stock.
Footnote F3
Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one hundred percent (100%) of the shares subject to the award shall vest on the one-year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean April 1, 2025.
SEC remarks
Chief Technical Operations Officer and SVP, Manufacturing Operations